Bone Biologics (OTC:BBLG) Trading Down 11.7% – Here’s What Happened

Shares of Bone Biologics Co. (OTC:BBLGGet Free Report) dropped 11.7% during mid-day trading on Wednesday . The company traded as low as $4.85 and last traded at $4.91. Approximately 59,228 shares traded hands during trading, an increase of 84% from the average daily volume of 32,149 shares. The stock had previously closed at $5.56.

Bone Biologics Price Performance

The stock has a market cap of $16.06 million, a PE ratio of -0.10 and a beta of 0.75. The stock has a 50-day simple moving average of $4.49 and a 200-day simple moving average of $5.49.

About Bone Biologics

(Get Free Report)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.

Featured Stories

Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.